Lars Kaiser

Lars Kaiser

Auto-generated profile, based on publicly available information

Lars Kaiser

Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Center for Anesthesia Research Excellence, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2025 in Anaesthesia
Verified
Journal Article
Closed access
LKLars Kaiser
Lars Kaiser
BPBéla‐Simon Paschold
Béla‐Simon Paschold
LWLuca J. Wachtendorf
Luca J. Wachtendorf
EAElena Ahrens
Elena Ahrens
TTTheresa Tenge
Theresa Tenge
MSMaximilian Sebastian Schaefer
Maximilian Sebastian Schaefer

4 December 2025 in Anesthesiology
Verified
Journal Article
Closed access
LWLuca J. Wachtendorf
Luca J. Wachtendorf
LKLars Kaiser
Lars Kaiser
EAElena Ahrens
Elena Ahrens
TTTheresa Tenge
Theresa Tenge
SRSophia Riesemann
Sophia Riesemann
MSMaximilian Sebastian Schaefer
Maximilian Sebastian Schaefer
Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.

31 January 2026 in eClinicalMedicine
Verified
Journal Article
Open access
SRSophia Riesemann
Sophia Riesemann
TTTheresa Tenge
Theresa Tenge
EAElena Ahrens
Elena Ahrens
LWLuca J. Wachtendorf
Luca J. Wachtendorf
BPBéla-Simon Paschold
Béla-Simon Paschold
MSMaximilian Sebastian Schaefer
Maximilian Sebastian Schaefer
Postoperative delirium is a frequent, serious complication triggered by various factors including systemic inflammation. Dexamethasone, an inexpensive anti-inflammatory steroid frequently administered for prophylaxis of postoperative nausea and vomiting, attenuates inflammation. We hypothesised that intraoperative dexamethasone administration is associated with a lower risk of postoperative delirium and assessed whether this is modified by the occurrence of its key side effect, hyperglycaemia. This retrospective cohort study analysed electronic health data from adult hospitalised patients undergoing non-cardiac, non-neurosurgical, and non-transplant procedures at Beth Israel Deaconess Medical Center (Boston, MA, USA) between January 1, 2008, and January 15, 2024. Patients with missing data, preoperative delirium or glucocorticoid use, mechanical ventilation for 72 h or more, and those not expected to survive without the procedure, were excluded. The primary exposure was intraoperative administration of intravenous dexamethasone. The primary outcome was 7-day postoperative delirium, identified by keyword-triggered manual discharge note reviews, diagnostic codes, and the Confusion Assessment Method. Hyperglycaemia was defined as peak 24-h postoperative blood glucose of more than 180 mg/dL. All analyses were adjusted for 43 patient-related and procedure-related variables. 92,832 patients were included (55.8% female, median age 60 years [IQR 48–70]), of which 41,983 (45.2%) received dexamethasone at a median dose of 8 mg (IQR 4–8). 2575 (2.8%) patients developed postoperative delirium. Emergency procedures accounted for 11,970 (12.9%) of cases. Intraoperative administration of dexamethasone was associated with a lower risk of delirium (adjusted odds ratio [aOR] 0.63, 95% CI 0.56–0.70; p < 0.001; adjusted absolute risk difference −1.1%, 95% CI −1.3 to −0.8). The exploratory four-way mediation analysis suggested a 10.4% greater dexamethasone-associated reduction of postoperative delirium risk when hyperglycaemia did not occur (no hyperglycaemia aOR 0.59, 95% CI 0.51–0.67; p < 0.001; hyperglycaemia aOR 0.85, 95% CI 0.68–1.07; p = 0.17). Intraoperative dexamethasone administration is associated with a lower risk of postoperative delirium, although this association was not evident in patients experiencing hyperglycaemia. Prospective studies should investigate the role of dexamethasone and optimised blood glucose control in delirium prevention. Unrestricted philanthropic grant by Dr. J. and J. Buzen.